查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1461309

PD-1 和 PD-L1 抑制劑市場、依抑制劑類型、依癌症類型、依配銷通路、依地理區域

PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

PD-1和PD-L1抑制劑市場預計2024年價值525.1億美元，預計到2031年將達到1,700.1億美元，2024年至2031年年複合成長率（CAGR）為18.3%。

報告範圍 報告詳情
基準年： 2023年 2023/2024 年市場規模： 525.1 億美元
歷史數據： 2019年至2023年 預測期： 2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率： 18.30% 2030/2031 價值預測： 1700.1 億美元
PD-1 和 PD-L1 抑制劑市場佔有率 (%)（依地區），2024 年
PD-1 和 PD-L1 抑制劑市場 - IMG1

PD-1和PD-L1抑制劑是免疫檢查點抑制劑，在癌症治療中顯示出有希望的結果。檢查點抑制劑透過阻斷 PD-1 和 PD-L1 蛋白質來幫助增強人體的自然抗腫瘤反應，這些蛋白質有助於腫瘤逃避免疫系統的攻擊。透過阻斷這些蛋白質，檢查點抑制劑使稱為 T 細胞的免疫系統細胞能夠更有效地識別和攻擊癌細胞。近年來，多種 PD-1 和 PD-L1 抑制劑已被批准用於治療多種癌症，如黑色素瘤、肺癌等。與傳統療法相比，這些抑制劑的臨床結果有所改善，因此其市場已大幅成長，預計未來幾年將出現高速成長。

市場動態：

全球PD-1和PD-L1抑制劑市場的成長是由全球癌症盛行率上升以及免疫檢查點抑制劑因其有前景的臨床療效而在臨床實踐中越來越多的採用所推動的。此外，用於其他癌症適應症的新型 PD-1 和 PD-L1 抑制劑的批准和推出進一步推動了市場成長。然而，市場面臨著開發和製造這些藥物的高成本以及昂貴的定價的限制，限制了廣泛採用。正在進行的臨床試驗評估檢查點抑制劑與其他抗癌療法相結合的潛力，從長遠來看，為市場參與者提供了利潤豐厚的機會。

研究的主要特點：

  • 該報告對全球PD-1和PD-L1抑制劑市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模和年複合成長率（CAGR%） 。
  • 它闡明了不同細分市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
  • 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
  • 它根據以下參數（公司亮點、產品組合、主要亮點、財務業績和策略）介紹了全球 PD-1 和 PD-L1 抑制劑市場的主要參與者。
  • 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 全球 PD-1 和 PD-L1 抑制劑市場報告面向該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
  • 利害關係人可以透過用於分析全球 PD-1 和 PD-L1 抑制劑市場的各種策略矩陣輕鬆做出決策。

目錄：

第1章：研究目標與假設

  • 研究目標
  • 假設
  • 縮寫

第 2 章：市場範圍

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
  • Coherent Opportunity Map (COM)

第 3 章：市場動態、法規與趨勢分析

  • 市場動態
    • 癌症發生率/盛行率上升
    • 癌症治療費用高
    • 研究和開發活動的增加
  • 影響分析
  • 主要亮點
  • 監管場景
  • 產品發布/批准
  • PEST分析
  • 波特的分析
  • 併購場景

第 4 章：全球 PD-1 和 PD-L1 抑制劑市場 - 冠狀病毒 (COVID-19) 大流行的影響

  • COVID-19 流行病學
  • 供給面和需求面分析
  • 經濟影響

第 5 章：2019-2031 年全球 PD-1 和 PD-L1 抑制劑市場（依抑制劑類型）

  • 介紹
  • PD-1抑制劑
  • PD-L1抑制劑

第 6 章：2019-2031 年全球 PD-1 和 PD-L1 抑制劑市場（依癌症類型）

  • 介紹
  • 腎
  • 黑色素瘤
  • 膀胱
  • 非小細胞肺癌
  • 肝
  • 頭頸
  • 其他

第 7 章：全球 PD-1 和 PD-L1 抑制劑市場，依配銷通路，2019-2031 年

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 8 章：2019-2031 年全球 PD-1 和 PD-L1 抑制劑市場（依地區）

  • 介紹
  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 歐洲其他地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 東協
  • 澳洲
  • 韓國
  • 亞太地區其他地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
  • 中東
  • 海灣合作理事會
  • 以色列
  • 中東其他地區
  • 非洲
  • 北非
  • 中非
  • 南非

第 9 章：競爭格局

  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca PLC
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Sanofi AG
  • F. Hoffmann-La Roche AG
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD

第 10 章：分析師觀點

  • 命運之輪
  • 分析師觀點
  • 連貫的機會圖

第 11 章：參考文獻與研究方法

  • 參考
  • 研究方法論
簡介目錄
Product Code: CMI173

The PD-1 and PD-L1 inhibitor market is estimated to be valued at USD 52.51 Bn in 2024 and is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 52.51 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 18.30% 2030/2031 Value Projection: US$ 170.01 Bn
PD-1 and PD-L1 Inhibitor Market Share (%), By Region, 2024
PD-1 and PD-L1 Inhibitor Market - IMG1

PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.

Market Dynamics:

The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.

Key Features of the Study:

  • This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.

Market Segmentation

  • Type of Inhibitor:
    • PD-1 Inhibitors
    • PD-L1 Inhibitors
  • Cancer Type:
    • Kidney
    • Melanoma
    • Bladder
    • Non-small Cell Lung Cancer
    • Liver
    • Head & neck
    • Others
  • Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer Inc.
    • Novartis AG
    • AstraZeneca PLC
    • Gilead Sciences Inc.
    • Amgen Inc.
    • Sanofi AG
    • Hoffmann-La Roche AG
    • Merck & Co.
    • Bristol-Myers Squibb Company
    • Regeneron Pharmaceuticals Inc.
    • Merck & Co.
    • GSK plc
    • Ono Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • BeiGene LTD

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type of Inhibitor
    • Market Snapshot, By Cancer Type
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in incidence/prevalence of cancer
    • High cost of cancer treatment
    • Rise in research and development activities
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • PD-1 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • PD-L1 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Kidney
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Bladder
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Non-small Cell Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Liver
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Head & Neck
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Gilead Sciences Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi AG
  • F. Hoffmann-La Roche AG
  • Merck & Co.
  • Bristol-Myers Squibb Company
  • Regeneron Pharmaceuticals Inc.
  • GSK plc
  • Ono Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • BeiGene LTD

10. Analyst View

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact